Margot N - Search Results

1

Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.

Cox S, Margot N, Ram R, Johnson A, Miller M, Callebaut C. Cox S, et al. Among authors: margot n. Antiviral Res. 2017 Jul;143:22-29. doi: 10.1016/j.antiviral.2017.03.021. Epub 2017 Mar 28. Antiviral Res. 2017. PMID: 28363735

2

Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

Miller MD, Lamy PD, Fuller MD, Mulato AS, Margot NA, Cihlar T, Cherrington JM. Miller MD, et al. Among authors: margot na. Mol Pharmacol. 1998 Aug;54(2):291-7. doi: 10.1124/mol.54.2.291. Mol Pharmacol. 1998. PMID: 9687570

3

In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM. Wainberg MA, et al. Among authors: margot na. Antivir Ther. 1999;4(2):87-94. doi: 10.1177/135965359900400205. Antivir Ther. 1999. PMID: 10682153

4

Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.

Naeger LK, Margot NA, Miller MD. Naeger LK, et al. Among authors: margot na. Antivir Ther. 2001 Jun;6(2):115-26. Antivir Ther. 2001. PMID: 11491416

5

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM. Miller MD, et al. Among authors: margot na. J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):450-8. doi: 10.1097/00126334-200108150-00005. J Acquir Immune Defic Syndr. 2001. PMID: 11511821 Clinical Trial.

6

Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.

Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R Jr, Miller M. Palmer S, et al. Among authors: margot n. AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1167-73. doi: 10.1089/088922201316912772. AIDS Res Hum Retroviruses. 2001. PMID: 11522186

7

Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Miller MD, et al. Among authors: margot na. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1025-8. doi: 10.1081/NCN-100002483. Nucleosides Nucleotides Nucleic Acids. 2001. PMID: 11562951

8

Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.

Naeger LK, Margot NA, Miller MD. Naeger LK, et al. Among authors: margot na. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):635-9. doi: 10.1081/NCN-100002340. Nucleosides Nucleotides Nucleic Acids. 2001. PMID: 11563081

9

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Margot NA, et al. AIDS. 2002 Jun 14;16(9):1227-35. doi: 10.1097/00002030-200206140-00004. AIDS. 2002. PMID: 12045487 Clinical Trial.

10

ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.

Naeger LK, Margot NA, Miller MD. Naeger LK, et al. Antimicrob Agents Chemother. 2002 Jul;46(7):2179-84. doi: 10.1128/AAC.46.7.2179-2184.2002. Antimicrob Agents Chemother. 2002. PMID: 12069972 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters